173 related articles for article (PubMed ID: 29374709)
1. Non-invasive Detection of Bladder Tumors Through Volatile Organic Compounds: A Pilot Study with an Electronic Nose.
Heers H; Gut JM; Hegele A; Hofmann R; Boeselt T; Hattesohl A; Koczulla AR
Anticancer Res; 2018 Feb; 38(2):833-837. PubMed ID: 29374709
[TBL] [Abstract][Full Text] [Related]
2. Pilot study for bladder cancer detection with volatile organic compounds using ion mobility spectrometry: a novel urine-based approach.
Heers H; Gut JM; Hofmann R; Flegar L; Derigs M; Huber J; Baumbach JI; Koczulla AR; Boeselt T
World J Urol; 2024 May; 42(1):353. PubMed ID: 38795133
[TBL] [Abstract][Full Text] [Related]
3. VOC-based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine-based approach.
Heers H; Chwilka O; Huber J; Vogelmeier C; Koczulla AR; Baumbach JI; Boeselt T
Prostate; 2024 Jun; 84(8):756-762. PubMed ID: 38497426
[TBL] [Abstract][Full Text] [Related]
4. Volatile organic compounds as biomarkers of bladder cancer: Sensitivity and specificity using trained sniffer dogs.
Willis CM; Britton LE; Harris R; Wallace J; Guest CM
Cancer Biomark; 2010-2011; 8(3):145-53. PubMed ID: 22012770
[TBL] [Abstract][Full Text] [Related]
5. Urinary survivin mRNA expression and urinary nuclear matrix protein 22 BladderChek® and urine cytology in the detection of transitional cell carcinoma of the bladder.
Al-Maghrebi M; Kehinde EO; Kapila K; Anim JT
Med Princ Pract; 2012; 21(3):295-7. PubMed ID: 22236881
[TBL] [Abstract][Full Text] [Related]
6. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
Jamshidian H; Kor K; Djalali M
Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis.
Curigliano G; Ferretti G; Flamini G; Goldhirsch A; de Braud F; Calabro MG; Mandaly M; Nole F; De Pas T; D'Addessi A; Cittadini A
Anticancer Res; 2001; 21(4B):3015-20. PubMed ID: 11712804
[TBL] [Abstract][Full Text] [Related]
8. Non-Invasive Diagnosis of Diabetes by Volatile Organic Compounds in Urine Using FAIMS and Fox4000 Electronic Nose.
Esfahani S; Wicaksono A; Mozdiak E; Arasaradnam RP; Covington JA
Biosensors (Basel); 2018 Dec; 8(4):. PubMed ID: 30513787
[TBL] [Abstract][Full Text] [Related]
9. Investigation of urinary volatile organic compounds as novel diagnostic and surveillance biomarkers of bladder cancer.
Lett L; George M; Slater R; De Lacy Costello B; Ratcliffe N; García-Fiñana M; Lazarowicz H; Probert C
Br J Cancer; 2022 Jul; 127(2):329-336. PubMed ID: 35352020
[TBL] [Abstract][Full Text] [Related]
10. BTA TRAK urine test increases the efficacy of cytology in the diagnosis of low-grade transitional cell carcinoma of the bladder.
Gibanel R; Ribal MJ; Filella X; Ballesta AM; Molina R; Alcaraz A; Alcover JB
Anticancer Res; 2002; 22(2B):1157-60. PubMed ID: 12168917
[TBL] [Abstract][Full Text] [Related]
11. Electronic nose can discriminate colorectal carcinoma and advanced adenomas by fecal volatile biomarker analysis: proof of principle study.
de Meij TG; Larbi IB; van der Schee MP; Lentferink YE; Paff T; Terhaar Sive Droste JS; Mulder CJ; van Bodegraven AA; de Boer NK
Int J Cancer; 2014 Mar; 134(5):1132-8. PubMed ID: 23959518
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive molecular detection of bladder cancer recurrence.
Amira N; Mourah S; Rozet F; Teillac P; Fiet J; Aubin P; Cortesse A; Desgrandchamps F; Le Duc A; Cussenot O; Soliman H
Int J Cancer; 2002 Sep; 101(3):293-7. PubMed ID: 12209982
[TBL] [Abstract][Full Text] [Related]
13. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
14. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma.
Passerotti CC; Srougi M; Bomfim AC; Martins JR; Leite KR; Dos Reis ST; Sampaio LO; Ortiz V; Dietrich CP; Nader HB
Urol Oncol; 2011; 29(6):710-5. PubMed ID: 19962919
[TBL] [Abstract][Full Text] [Related]
15. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment.
Bartoletti R; Dal Canto M; Cai T; Piazzini M; Travaglini F; Gavazzi A; Rizzo M
Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429
[TBL] [Abstract][Full Text] [Related]
16. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
[TBL] [Abstract][Full Text] [Related]
17. Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder.
Korman HJ; Peabody JO; Cerny JC; Farah RN; Yao J; Raz A
J Urol; 1996 Jan; 155(1):347-9. PubMed ID: 7490884
[TBL] [Abstract][Full Text] [Related]
18. [Non-invasive urinary diagnosis of bladder cancer. What do we know?].
Kausch I; Böhle A
Urologe A; 2003 Jul; 42(7):912-21. PubMed ID: 12898034
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
20. Combinations of urine-based tumour markers in bladder cancer surveillance.
Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
